Global medical device company, St. Jude Medical, Inc. recently announced that it has launched its EnSite Precision cardiac mapping system and new Sensor Enabled tools in Europe. The new platform is now installed on and active in more than 100 sites across Europe.
St. Jude’s EnSite Precision cardiac mapping system provides highly detailed anatomical models and maps to effectively enable diagnosis of a wide range of arrhythmias and guide therapy. The system combines magnetic and impedance technologies to transform procedures with intuitive automation. The EnSite Precision cardiac mapping system is flexible and enhances workflow efficiency by allowing physicians to optimize mapping of the heart chambers.
The EnSite Precision cardiac mapping system also allows real-time catheter navigation using minimal fluoroscopy. This reduces risks associated with excessive radiation exposure in patients and clinicians.
In addition to Europe, the EnSite Precision cardiac mapping system is available in other markets, including Hong Kong and Singapore. St. Jude Medical is pursuing Food and Drug Administration clearance to make the system available in the U.S.
St. Jude is well positioned to benefit from the growing adoption of CardioMEMS, which is a first-of-its-kind FDA-approved heart failure monitoring device. The company believes that CardioMEMS has immense growth potential owing to its ability to reduce hospital readmission rates in heart failure patients.
Most recently, new data from Northwell Health demonstrated that monitoring pulmonary artery pressure with the CardioMEMS technology leads to significant improvement in the quality of life. The study monitored 34 New York Heart Association (NYHA) Class III heart failure patients. For 2016, sales expectation from this product line is approximately $65 million. St. Jude plans to pioneer an entirely new market with CardioMEMS and expects the same to become a major new growth driver in the long run.
Headquartered in St. Paul, MN, St. Jude Medical has approximately 18,000 employees worldwide and focuses on five major areas that include heart failure, atrial fibrillation, neuron modulation, traditional cardiac rhythm management and cardiovascular.
A few notable stocks in the medical product sector are Quidel Corp. (QDEL - Free Report) , NuVasive, Inc. (NUVA - Free Report) and GW Pharmaceuticals plc (GWPH - Free Report) .
Quidel is expected to record earnings growth of 20%, higher than the industry average of 14.8% over the next five years. It has a four-quarter average earning surprise of 59.39%.
NuVasive has a trailing four-quarter average earning surprise of 18.98%. For the past five years, the stock saw a 16.6% earnings growth compared to the industry average of 5%.
GW Pharmaceuticals has a four-quarter average earning surprise of 41.67%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>